Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TYMP | P19971 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3924762 | 0.93 | TK1 (0.39) | TK1MAPK1HPGDTYMP | |
| SCHEMBL3920039 | 0.92 | TK1 (0.39) | TK1MAPK1HPGDTYMP | |
| SCHEMBL3930081 | 0.91 | TK1 (0.40) | TK1MAPK1 | |
| SCHEMBL3926875 | 0.89 | TK1 (0.40) | TK1MAPK1HPGDTYMP | |
| SCHEMBL3918737 | 0.89 | TK1 (0.40) | TK1MAPK1HPGD | |
| SCHEMBL7529489 | 0.84 | HPGD (0.43) | TK1MAPK1HPGDTYMP | |
| SCHEMBL6837658 | 0.83 | MAPK1 (0.40) | TK1MAPK1HPGDTYMP | |
| SCHEMBL8720371 | 0.82 | KMT2A (0.47) | TK1MAPK1HPGDTYMP | |
| SCHEMBL8725737 | 0.82 | KMT2A (0.39) | TK1MAPK1HPGDTYMP | |
| SCHEMBL8645221 | 0.79 | TK1 (0.42) | TK1MAPK1HPGDTYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485421-B2 | Polyamide-oligonucleotide derivatives, their preparation and use | HOECHST GMBH (DE) | 2009-02-03 | — | — | US | disclosed |
| EP-1113021-B1 | Polyamide-oligonucleotide derivatives, their production and use | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-08-09 | — | — | EP | disclosed |
| US-6919441-B2 | Polyamide-oligonucleotide derivatives, their preparation and use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-07-19 | — | — | US | disclosed |
| US-20050026817-A1 | Polyamide-oligonucleotide derivatives, their preparation and use | AVENTIS PHARMA DEUTSCHLAND GMBH (US) | 2005-02-03 | — | — | US | disclosed |
| US-6756199-B1 | USED FOR THE SYNTHESIS OF BOTH PREDEFINED AND RANDOM SEQUENCE PEPTIDE NUCLEIC ACID OLIGOMERS | ISIS PHARMACEUTICALS, INC. | 2004-06-29 | — | — | US | disclosed |
| EP-1113021-A2 | Polyamide-oligonucleotide derivatives, their production and use | Aventis Pharma Deutschland GmbH (DE) | 2001-07-04 | — | — | EP | disclosed |
| US-6204326-B1 | ADDING PEPTIDE NUCLEIC ACID UNITS TO AN AMINE TERMINATED PEPTIDE NUCLEIC ACID OLIGOMER ON A SOLID PHASE SYNTHETIC RESIN; BIOSYNTHESIS | ISIS PHARMACEUTICALS, INC. | 2001-03-20 | — | — | US | disclosed |
| EP-0777678-B1 | PNA COMBINATORIAL LIBRARIES AND IMPROVED METHODS OF SYNTHESIS | ISIS PHARMACEUTICALS INC (US) | 1999-10-13 | — | — | EP | disclosed |
| US-5864010-A | ENZYME INHIBITOR; ANTIINFLAMMATORY AGENT | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-26 | — | — | US | disclosed |
| US-5831014-A | OLIGOMERS WITH PEPTIDE NUCLEIC ACID UNITS AND AMINO ACID UNITS | ISIS PHARMACEUTICALS, INC. (US) | 1998-11-03 | — | — | US | disclosed |
| US-5539083-A | FROM HALOACETYL HALIDE OR SULFONYLACETYL HALIDE, PROTECTED ALKYLENEDIAMINE, AND A DERIVATIVE OF A NUCLEIC ACID BASE | ISIS PHARMACEUTICALS, INC. (US) | 1996-07-23 | — | — | US | disclosed |
| EP-0672677-A2 | Polyamide-oligonucleotide derivatives, their production and use | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026817-A1 | Polyamide-oligonucleotide derivatives, their preparation and use | POLRMT, POLR2H, POLN | TK1 264/4885MAPK1 3965/4885HPGD 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.